Mesh Augmented Reinforcement of Abdominal Wall Suture Line to Limit the Rate of Incisional Hernia Occurrence (MARS)
Primary Purpose
Incisional Hernia, Incisional Hernia of Midline of Abdomen, Midline Laparotomy
Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Self-Gripping Resorbable Mesh
Sponsored by
About this trial
This is an interventional prevention trial for Incisional Hernia focused on measuring Incisional Hernia, Prophylactic Mesh, Incisional Hernia of Midline of Abdomen, Midline Laparotomy
Eligibility Criteria
Inclusion Criteria:
- Subject has provided informed consent.
- Subject is ≥18 years of age at the time of consent.
- Subject will be undergoing an elective surgery with a planned midline laparotomy with retrorectus mesh placement.
Pre-Operative Exclusion Criteria:
- Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death
- Subject has a history of allergic reactions after application of poly-L-lactide, poly-trimethylene carbonate copolymers (PLLA/TMC)
- Subject is pregnant or is planning pregnancy during study duration period (Females of child-bearing potential will be required to provide either a urine or serum pregnancy test (except for subjects who are surgically sterile or are at least 2 years postmenopausal))
- Subject is unable or unwilling to comply with the study requirements or follow-up schedule
- Subject is scheduled for another planned surgery, and subsequent surgery would jeopardize previous application of study treatment
- Subject with a body mass index (BMI) > 45 kg/m2
- Subjects with the following medical interventions/medical conditions are excluded from participation in the study: uncontrolled diabetes (hemoglobin A1c (Hb1Ac) > 60mmol/mol), cirrhosis, stoma wearers
- Concomitant ostomy (stoma creation or closure)
- Subject who had received a mesh in a previous ventral hernia repair or has an existing ventral hernia.
- Subject with a life expectancy inferior to the study follow-up duration (36 months)
- Study procedure is a relaparotomy within 30 days of previous abdominal surgery
- Subject with an American Society of Anesthesiologists (ASA) scores higher than 3
- Subject has participated in an investigation drug or device study within 30 days of enrolment
- Subject with current chemo and/or radiation therapy within 2 weeks of procedure
- Subject with history of ascites
- Subject has a medical condition that precludes the patient from participation in the opinion of the investigator
- Subject is undergoing a vascular procedure other than abdominal aortic aneurysm (AAA) surgery (i.e, only AAA surgeries accepted)
Intraoperative Exclusion criteria
- Subject's study procedure is in a contaminated or infected site as assessed by the Investigator(s) (CDC Class 3 and 4)
- Abdomen is left open at the end of the procedure
- Subject has an unsuspected ventral hernia >1cm encountered at the time of laparotomy
- Inability to close the anterior fascia or keep the mesh securely out of the peritoneal cavity
- Second-look procedure planned
- Cases requiring a full-thickness partial resection of the abdominal wall (in particular the midline) because of involvement in neoplastic process or complex fistula
- Inoperable tumor/poor prognostic cancer/patient non curatively treated
- Subject has a suture length to wound length ratio< 3.5/1
- Subject has any ongoing infection at the time of the surgery, that is uncontrolled and/or requiring treatment such as antibiotics
- Subject was not implanted with Deternia™ Self Gripping Resorbable Mesh
- Subject requires more than 1 mesh
Sites / Locations
- Clinical Hospital Center Sisters of MercyRecruiting
- University Hospital Center of ZagrebRecruiting
- Klinikum BraunschweigRecruiting
- Pius-Hospital Medical Campus University of OldenburgRecruiting
- Barmherzige Brüder RegensburgRecruiting
- IJsselland ZiekenhuisRecruiting
- Maastricht University Medical CenterRecruiting
- Hospital de la Santa Creu i Sant PauRecruiting
- Hospital Universitario Ramón y CajalRecruiting
- Hospital Universitario Virgen MacarenaRecruiting
- Countess Of Chester Hospital NHS Foundation TrustRecruiting
- Cardiff and Vale University Local Health BoardRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Hernia prevention cohort
Arm Description
single arm study, no control arm
Outcomes
Primary Outcome Measures
Incisional Hernia Rate
Occurrence of incisional hernia assessed by clinical examination and abdominal ultrasound exam
Secondary Outcome Measures
Incisional Hernia Rate
Occurrence of incisional hernia assessed by clinical examination and abdominal ultrasound exam
Incisional Hernia Rate
Occurrence of incisional hernia assessed by clinical examination
Time to Incisional Hernia
Time from surgery to incisional hernia
Time to other adverse device effects (ADE)
Time from skin incision to ADE
Incidence of all adverse device effects (ADEs)
Adverse device effects related to mesh and mesh-augmented reinforcement procedure
Incidence of adverse events (AEs) of interest
AEs of interest: symptomatic seroma requiring action taken, hematoma needing surgical revision, surgical site infection (SSI) defined via the CDC classification of SSI (superficial, deep or organ space), wound dehiscence (skin and/or fascial), mesh removal
Pain at the site of surgery evaluated with Numeric Rating Scale (NRS)
Scale from 0-10, with 0 being no pain and 10 being the worst imaginable pain
EQ-5D-5L quality of life (QoL)
Self-administered QOL questionnaire with 5 questions on quality of life and a numeric scale from 0-100 with 0 being the worst health you can imagine and 100 being the best health you can imagine.
Surgeon Satisfaction
Surgeon satisfaction questionnaire on mesh use
Hospital length of stay
Amount of time spent inpatient
Readmission and reoperation rate
Related to Mesh device and/or Mesh Augmented Reinforcement procedure.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05424484
Brief Title
Mesh Augmented Reinforcement of Abdominal Wall Suture Line to Limit the Rate of Incisional Hernia Occurrence
Acronym
MARS
Official Title
Mesh Augmented Reinforcement of Abdominal Wall Suture Line in Patients Undergoing Midline Laparotomy to Limit the Rate of Incisional Hernia Occurrence
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 10, 2022 (Actual)
Primary Completion Date
May 2025 (Anticipated)
Study Completion Date
May 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic - MITG
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this prospective, pivotal, multi-center, single-arm cohort, pre-market, investigational clinical study is to assess the safety and performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II). Data from this study will be used to support market applications. The indication under investigation is reinforcement of midline laparotomy to limit the rate of incisional hernia (IH) in clean and clean-contaminated surgeries (CDC Classification I and II).
Detailed Description
The primary objective of this investigation is to evaluate the performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after elective midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II) at 12 months post-operatively and to demonstrate expected performance in terms of rate of IH occurrence relative to a performance goal (based on historical data on primary laparotomy incision suture closure with small bites only).
The secondary objectives are to evaluate the safety and performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after elective midline laparotomy in clean and clean contaminated fields (CDC Classification I and II) within 36 months postoperatively.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Incisional Hernia, Incisional Hernia of Midline of Abdomen, Midline Laparotomy
Keywords
Incisional Hernia, Prophylactic Mesh, Incisional Hernia of Midline of Abdomen, Midline Laparotomy
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Hernia prevention cohort
Arm Type
Experimental
Arm Description
single arm study, no control arm
Intervention Type
Device
Intervention Name(s)
Self-Gripping Resorbable Mesh
Intervention Description
Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
Primary Outcome Measure Information:
Title
Incisional Hernia Rate
Description
Occurrence of incisional hernia assessed by clinical examination and abdominal ultrasound exam
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Incisional Hernia Rate
Description
Occurrence of incisional hernia assessed by clinical examination and abdominal ultrasound exam
Time Frame
24- and 36-months
Title
Incisional Hernia Rate
Description
Occurrence of incisional hernia assessed by clinical examination
Time Frame
3-, 6-, 12-, 24-, and 36- months
Title
Time to Incisional Hernia
Description
Time from surgery to incisional hernia
Time Frame
From the surgery to the 36-month visit
Title
Time to other adverse device effects (ADE)
Description
Time from skin incision to ADE
Time Frame
From the surgery to the 36-month visit
Title
Incidence of all adverse device effects (ADEs)
Description
Adverse device effects related to mesh and mesh-augmented reinforcement procedure
Time Frame
Intra-operatively, at discharge (post-surgery up to 3-mo), and within 3-, 6-, 12-, 24-, and 36- months
Title
Incidence of adverse events (AEs) of interest
Description
AEs of interest: symptomatic seroma requiring action taken, hematoma needing surgical revision, surgical site infection (SSI) defined via the CDC classification of SSI (superficial, deep or organ space), wound dehiscence (skin and/or fascial), mesh removal
Time Frame
Intra-operatively, at discharge (post-surgery up to 3-mo), and within 3-, 6-, 12-, 24-, and 36- months
Title
Pain at the site of surgery evaluated with Numeric Rating Scale (NRS)
Description
Scale from 0-10, with 0 being no pain and 10 being the worst imaginable pain
Time Frame
baseline (screening), discharge (post-surgery up to 3-mo) and at 3-, 6-, 12-, 24-, and 36- months
Title
EQ-5D-5L quality of life (QoL)
Description
Self-administered QOL questionnaire with 5 questions on quality of life and a numeric scale from 0-100 with 0 being the worst health you can imagine and 100 being the best health you can imagine.
Time Frame
Baseline and at 3-, 6-, 12-, 24-, and 36- months
Title
Surgeon Satisfaction
Description
Surgeon satisfaction questionnaire on mesh use
Time Frame
Day 0, post-operative
Title
Hospital length of stay
Description
Amount of time spent inpatient
Time Frame
Hospital admission to hospital discharge (post-surgery up to 3-mo)
Title
Readmission and reoperation rate
Description
Related to Mesh device and/or Mesh Augmented Reinforcement procedure.
Time Frame
From the surgery to the 36-month visit
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subject has provided informed consent.
Subject is ≥18 years of age at the time of consent.
Subject will be undergoing an elective surgery with a planned midline laparotomy with retrorectus mesh placement.
Pre-Operative Exclusion Criteria:
Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death
Subject has a history of allergic reactions after application of poly-L-lactide, poly-trimethylene carbonate copolymers (PLLA/TMC)
Subject is pregnant or is planning pregnancy during study duration period (Females of child-bearing potential will be required to provide either a urine or serum pregnancy test (except for subjects who are surgically sterile or are at least 2 years postmenopausal))
Subject is unable or unwilling to comply with the study requirements or follow-up schedule
Subject is scheduled for another planned surgery, and subsequent surgery would jeopardize previous application of study treatment
Subject with a body mass index (BMI) > 45 kg/m2
Subjects with the following medical interventions/medical conditions are excluded from participation in the study: uncontrolled diabetes (hemoglobin A1c (Hb1Ac) > 60mmol/mol), cirrhosis, stoma wearers
Concomitant ostomy (stoma creation or closure)
Subject who had received a mesh in a previous ventral hernia repair or has an existing ventral hernia.
Subject with a life expectancy inferior to the study follow-up duration (36 months)
Study procedure is a relaparotomy within 30 days of previous abdominal surgery
Subject with an American Society of Anesthesiologists (ASA) scores higher than 3
Subject has participated in an investigation drug or device study within 30 days of enrolment
Subject with current chemo and/or radiation therapy within 2 weeks of procedure
Subject with history of ascites
Subject has a medical condition that precludes the patient from participation in the opinion of the investigator
Subject is undergoing a vascular procedure other than abdominal aortic aneurysm (AAA) surgery (i.e, only AAA surgeries accepted)
Intraoperative Exclusion criteria
Subject's study procedure is in a contaminated or infected site as assessed by the Investigator(s) (CDC Class 3 and 4)
Abdomen is left open at the end of the procedure
Subject has an unsuspected ventral hernia >1cm encountered at the time of laparotomy
Inability to close the anterior fascia or keep the mesh securely out of the peritoneal cavity
Second-look procedure planned
Cases requiring a full-thickness partial resection of the abdominal wall (in particular the midline) because of involvement in neoplastic process or complex fistula
Inoperable tumor/poor prognostic cancer/patient non curatively treated
Subject has a suture length to wound length ratio< 3.5/1
Subject has any ongoing infection at the time of the surgery, that is uncontrolled and/or requiring treatment such as antibiotics
Subject was not implanted with Deternia™ Self Gripping Resorbable Mesh
Subject requires more than 1 mesh
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ruth Larbre
Phone
+33 678213945
Email
ruth.larbre@medtronic.com
First Name & Middle Initial & Last Name or Official Title & Degree
Study Mailbox
Email
rs.marsstudy@medtronic.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jose M Molina, Dr
Organizational Affiliation
Hospital Universitario Ramon y Cajal, Madrid, Spain
Official's Role
Study Chair
Facility Information:
Facility Name
Clinical Hospital Center Sisters of Mercy
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mario Zovak, PhD
Facility Name
University Hospital Center of Zagreb
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Predrag Pavic, PhD
Facility Name
Klinikum Braunschweig
City
Braunschweig
ZIP/Postal Code
38118
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guido Schumacher, PhD
Facility Name
Pius-Hospital Medical Campus University of Oldenburg
City
Oldenburg
ZIP/Postal Code
26121
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dirk Weyhe, PhD
Facility Name
Barmherzige Brüder Regensburg
City
Regensburg
ZIP/Postal Code
93049
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Markus Steinbauer, PhD
Facility Name
IJsselland Ziekenhuis
City
Capelle aan den IJssel
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steve Buijk, PhD
Facility Name
Maastricht University Medical Center
City
Maastricht
ZIP/Postal Code
6229
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Bouvy, PhD
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Antonio Gonzalez Lopez, PhD
First Name & Middle Initial & Last Name & Degree
Jose Antonio Gonzalez Lopez, PhD
Facility Name
Hospital Universitario Ramón y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Manuel Molina Villar, MD
First Name & Middle Initial & Last Name & Degree
Jose Manuel Molina Villar, MD
Facility Name
Hospital Universitario Virgen Macarena
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juan Bellido Luque, MD
First Name & Middle Initial & Last Name & Degree
Juan Bellido Luque, MD
Facility Name
Countess Of Chester Hospital NHS Foundation Trust
City
Chester
State/Province
Cheshire
ZIP/Postal Code
CH2 1HJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dale Vimalachandran, MD
First Name & Middle Initial & Last Name & Degree
Dale Vimalachandran, MD
Facility Name
Cardiff and Vale University Local Health Board
City
Cardiff
ZIP/Postal Code
CF14 4XW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jared Torkington, MD
First Name & Middle Initial & Last Name & Degree
Jared Torkington, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Mesh Augmented Reinforcement of Abdominal Wall Suture Line to Limit the Rate of Incisional Hernia Occurrence
We'll reach out to this number within 24 hrs